Drug profile: Transdermal rivastigmine patch in the treatment of alzheimer disease

Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki, Teus Van Laar

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing therapeutic doses and poor patient compliance have been identified as barriers to effective treatment with these substances. The rivastigmine transdermal patch provides continuous delivery of drug through the skin into the bloodstream, avoiding the fluctuations in plasma concentration associated with oral administration. This pharmacokinetic profile is associated with reduced side effects, resulting in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, may contribute to enhanced patient compliance. Here, we present a review of the current literature on rivastigmine patch, and offer advice based on our own collective clinical experience. Rivastigmine patch provides an efficient option for managing patients with AD, to be considered among the first line therapies for the disease.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalCNS Neuroscience and Therapeutics
Issue number4
StatePublished - Aug 2010


  • Alzheimer's disease
  • Patch
  • Rivastigmine
  • Transdermal
  • Treatment


Dive into the research topics of 'Drug profile: Transdermal rivastigmine patch in the treatment of alzheimer disease'. Together they form a unique fingerprint.

Cite this